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Abstract
Background: Streptococcus pneumoniae causes widespread morbidity and mortality. Current vaccines contain free
polysaccharides or protein-polysaccharide conjugates, and do not induce protection against serotypes that are not
included in the vaccines. An affordable and broadly protective vaccine is very desirable. The goal of this study was
to determine the optimal formulation of a killed whole cell pneumococcal vaccine with aluminum-containing
adjuvants for intramuscular injection.
Methods: Four aluminium-containing adjuvants were prepared with different levels of surface phosphate groups
resulting in different adsorptive capacities and affinities for the vaccine antigens. Mice were immunized three times
and the antigen-specific antibody titers and IL-17 responses in blood were analyzed.
Results: Although all adjuvants induced significantly higher antibody titers than antigen without adjuvant, the
vaccine containing aluminum phosphate adjuvant (AP) produced the highest antibody response when low doses
of antigen were used. Aluminum hydroxide adjuvant (AH) induced an equal or better antibody response at high
doses compared with AP. Vaccines formulated with AH, but not with AP, induced an IL-17 response. The vaccine
formulated with AH was stable and retained full immunogenicity when stored at 4°C for 4 months.
Conclusions: Antibodies are important for protection against systemic streptococcal disease and IL-17 is critical in
the prevention of nasopharyngeal colonization by S. pneumoniae in the mouse model. The formulation of the
whole killed bacterial cells with AH resulted in a stable vaccine that induced both antibodies and an IL-17
response. These experiments underscore the importance of formulation studies with aluminium containing
adjuvants for the development of stable and effective vaccines.
Background
Streptococcus pneumoniae (pneumococcus) is a Gram-
positive, encapsulated diplococcus that is commonly
present as a commensal bacterium in the microbial flora
of the upper respiratory tract without causing clinical
disease. However, these bacteria also cause great mor-
bidity and mortality throughout the world. Pneumococ-
cal infections are a leading cause of pneumonia,
bacteremia, meningitis, and otitis media in adults and
children, and account for an estimated 1.6 million
deaths, including up to 1 million children less than 5
years of age, annually [1-3]. The burden of disease is
greatest in developing countries.
Based on differences in the composition of the poly-
saccharide capsule, more than 90 distinct serotypes of
pneumococcus are recognized. Current vaccines against
pneumococcus are a 23-valent vaccine containing free
polysaccharides and 7-valent, 10-valent and 13-valent
vaccines composed of protein-polysaccharide conjugates.
The free polysaccharides are T-independent antigens
and induce a poor immune response in children less
than 2 years of age. In contrast, the conjugated vaccines
that are T-dependent induce a good immune response
in young children and infants. These vaccines have
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otypes included in the vaccines in countries where these
vaccines are widely used. However, the vaccines do not
p r o t e c ta g a i n s ts e r o t y p e st h a ta r en o ti n c l u d e di nt h e
vaccine. Many serotypes in developing countries are not
included in the currently available vaccines and wide-
spread adoption of the vaccines is limited by the cost of
the polysaccharide and conjugate vaccines. Furthermore,
increased prevalence of non-vaccine serotypes has been
observed following the implementation of pneumococ-
cus vaccination programs [4,5]. These considerations
have led to the pursuit of alternative vaccination strate-
gies, including the use of protein antigens that are
shared among the different serotypes. A potentially suc-
cessful approach is the use of killed, non-encapsulated
pneumococci (whole cell antigen - WCA) which pro-
vides multiple common antigens for inducing an
immune response that is protective across the different
serotypes, and is relatively inexpensive to prepare [6].
Previous studies showed that intranasal immunization
with WCA and cholera toxin as a mucosal adjuvant,
induced a robust antibody response [7]. The inoculated
mice had greatly reduced nasopharyngeal and middle
ear colonization following intranasal administration of
pneumococci of different serotypes [7-9]. Similarly
inoculated rats were protected from sepsis against
intrathoracic challenge with serotype 3 [7]. The protec-
tion against nasopharyngeal colonization in mice
occurred in antibody-deficient mice, and was dependent
o nt h ep r e s e n c eo fC D 4
+ T cells. Subsequent studies
demonstrated that this protection was conferred by
Th17 cells, whereas IL-4 and IFN-g were not necessary
for protection [10].
Although mucosal administration of vaccines has sev-
eral advantages, the need for cholera toxin to induce an
effective immune response precludes this route of immu-
nization for human use until acceptable mucosal adju-
vants become available. Vaccines for intramuscular
injection often contain aluminum compounds as safe,
effective, and inexpensive adjuvants. The two aluminum-
containing adjuvants that are commercially available and
widely used in vaccines are aluminum hydroxide (AH)
and aluminum phosphate (AP) [11]. These adjuvants
have large adsorptive surfaces, but different structural
and surface properties which affect their interaction with
vaccine antigens. Adsorption of antigens onto aluminum
adjuvants increases the retention of antigens at the injec-
tion site and this property was considered essential for
the immunostimulatory effect ("depot-mechanism”).
However, recent studies indicate that adsorption is not
necessary for the adjuvant effect of aluminum com-
pounds [12-14]. Nevertheless, adsorption may affect the
structural stability of antigens and the availability of epi-
topes [15,16]. The two main mechanisms by which
antigens adsorb onto aluminum-containing adjuvants are
electrostatic attraction and ligand exchange [11]. The
surface charge of AH is positive at neutral pH and that of
AP is negative at neutral pH. Therefore, these adjuvants
have different affinities for antigens that adsorb through
electrostatic mechanisms. Electrostatically adsorbed anti-
gens usually elute from the adjuvants upon exposure to
interstitial fluid following intramuscular or subcutaneous
administration [17]. Ligand exchange is the replacement
of surface hydroxyls by terminal phosphate groups of
phosphorylated antigens creating a covalent bond that is
stronger than electrostatic adsorption. Since AH has
more surface hydroxyls than AP, it has a higher affinity
for phosphorylated antigens. Such strong adsorption
results in poor elution in interstitial fluid and has a nega-
tive effect on the immune response to phosphorylated
antigens formulated with AH as opposed to AP [18].
Our previous work with aluminium-containing adju-
vants was based on single antigens. Here, we report on
experiments aimed at formulating WCA, a complex
mixture of antigens, with aluminum adjuvants. The goal
was to determine the formulation that induced the max-
imum antibody and IL-17 response, two critical compo-
nents of a protective immune response against S.
pneumoniae [6]. These studies for the first time demon-
strate that the type of aluminum-containing adjuvants
(AH vs. AP) affects the magnitude and quality of the
antibody response as well as the Th17 CD4
+ T cell
response to WCA.
Methods
Mice
All experiments involving mice were conducted in accor-
dance with NIH guidelines for the care and use of experi-
mental animals and were approved by the Purdue
University Animal Care and Use Committee. Seven week
old female C57BL/6J mice were purchased from the Jack-
son Laboratory (Bar Harbor, ME). Mice were maintained
in a conventional barrier facility, exposed to a 12 h light/
12 h dark cycle, and allowed free access to water and
LabDiet 5015 (Purina Mills, Richmond, IN, USA). They
were acclimated for one week, and injected with 50 μlo f
vaccine intramuscularly in each hind leg (100 μL/mouse)
two or three times with a two-week interval. Immediately
prior to the last injection, blood was collected from the
facial vein. Two weeks after the last injection, mice were
anesthetized, blood was collected in heparinized tubes,
and the mice were euthanized. Serum and plasma were
separated by centrifugation at 14,000 × g for 10 min and
stored at -80°C until analysis.
Vaccine preparations
The whole cell bacterial antigen (WCA) consists of a
suspension of strain Rx1E, a capsule-deficient, autolysin-
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treatment with beta-propiolactone [19]. The stock solu-
tion (prepared by Instituto Butantan, Sao Paulo, Brazil)
contained 10
10 cells/mL (corresponding with 10 mg pro-
tein/mL) in Ringer’s solution.
Vaccines were prepared with 4 different adjuvants.
Aluminum hydroxide adjuvant (Alhydrogel “85” 2%) and
AP (AdjuPhos) were obtained from Brenntag Biosector
(Denmark). Phosphate-treated AH (PTAH) and phos-
phate treated AP (PTAP) were prepared by mixing the
adjuvants with 60 mM phosphate buffer for 16 hours at
room temperature.
Vaccines were prepared aseptically by adding different
amounts of WCA as indicated in the text to adjuvants
at 1.2 mg Al/mL and mixing for 1 h at room
temperature.
Adsorption isotherms
Vaccines were prepared as described above with differ-
ent WCA concentrations. After incubation for 1 h at 4°
C, the suspension was layered over a 60% sucrose gradi-
ent and centrifuged for 20 minutes at 1,500 × g to sepa-
rate non-adsorbed WCA from adsorbed WCA. The
supernatant was collected and protein content was
determined by bicinchoninic acid protein assay (Pierce,
Rockford, IL) in triplicate. The adsorption data was
plotted according to the linear form of the Langmuir
equation. The adsorptive coefficient was calculated as
the slope/intercept and the adsorptive capacity was cal-
culated as the reciprocal of the slope.
Light microscopy of vaccine preparations
The bacterial cells in WCA were stained with gentian
violet prior to mixing with AH and AP. The stained
cells were mixed with each adjuvant and examined by
light microscopy using a 100× oil immersion objective.
Anti-WCA ELISA
Ninety-six well plates were coated with WCA (10
8/mL)
overnight, blocked with 5% fetal calf serum diluted in
PBS, and incubated with serially diluted standard and
serum or plasma samples starting at a 1:100 dilution.
The plates were then incubated with peroxidase-labeled
goat anti-mouse IgG (Sigma, St. Louis, MO), followed
by 3,3’,5,5’ - tetramethylbenzidine substrate. After addi-
tion of a 2 N sulfuric acid stop solution the color inten-
sity was measured in a microplate reader (Biotek,
Winooski, VT) at 450 nm. A standard curve was con-
structed using serum with high antibody titer, arbitrarily
set at 120,000 U/mL.
Immunoblot of plasma samples
The WCA was diluted to 10
9/mL in lithium dodecyl sul-
fate (LDS) sample buffer (Thermo Fisher Scientific,
Rockford, IL) and incubated for 10 minutes at 70°C.
The proteins were separated on a 4-12% gradient gel
(Invitrogen) and transferred onto nitrocellulose. Indivi-
dual strips were blocked with non-fat milk, incubated
with pooled plasma at 1:500 dilution from each of the
experimental groups, and then with peroxidase-labeled
goat anti-mouse IgG. Bands were visualized with an
ECL detection kit.
IL-17 assay
Forty microliters of heparinized blood was added to 360
μLo fI s c o v e ’s Modified Eagle Medium supplemented
with 10% fetal calf serum, 10 μg/mL ciprofloxacin, and
10
7 WCA/mL. After incubation for 6 days at 37°C and
5% CO2, supernatants were collected and stored at -80°
C until analysis by ELISA for IL-17A (IL17; R&D Sys-
tems, Minneapolis, MN).
Statistical analysis
The anti-WCA IgG concentrations were log2 trans-
formed prior to analysis by one-way ANOVA followed
by a Newman-Keuls multiple comparison test (Graph-
pad Prism, version 5.02). Differences between groups at
p < 0.05 were considered significant. The statistical sig-
nificance of differences between means of IL-17 among
experimental groups was determined by two-way
ANOVA followed by Bonferroni post-hoc test with p <
0.05.
Results
Adsorption of WCA onto aluminum-containing adjuvants
Four different adjuvants were prepared and incubated
with different doses of WCA to determine the adsorp-
tive capacity and coefficient. The adsorptive capacity
and adsorptive coefficient (adsorptive strength) of AH
was greatest, followed by AP and then PTAH (Table 1).
There was no detectable adsorption of protein to PTAP.
The adsorption of the bacterial cells to each adjuvant
was verified by light microscopy using gentian violet-
stained bacteria (Figure 1). The bacteria were associated
with the AH and AP aggregates and were not observed
in the liquid phase separating the adjuvant aggregates.
Table 1 Adsorptive capacity and adsorptive coefficient
(affinity) of the different adjuvants for WCA calculated
from Langmuir adsorption isotherms.
Langmuir isotherm
coefficient
WCA/
AH
WCA/
AP
WCA/
PTAH
WCA/
PTAP
Adsorptive capacity
(mg/mg Al)
0.22 0.07 0.03 -
a
Adsorptive coefficient
(mL/mg)
4500 2026 803 -
a
a Adsorptive capacity and coefficient could not be determined because there
was no detectable adsorption.
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gely present in the liquid regions. These bacteria were
m o v i n gf r e e l yb yB r o w n i a nm o t i o nw h i l et h ec e l l sa s s o -
ciated with the AH and AP adjuvant aggregates were
stationary. Thus, the observations by light microscopy
concurred with the data derived from the adsorption
isotherms (Table 1).
Antibody response to vaccines formulated with four
different adjuvants
Mice were injected with WCA (10
7 cells) alone or com-
bined with one of the four adjuvants. After two injec-
tions, blood was collected and the concentration of anti-
WCA IgG was determined. All four adjuvants enhanced
the antibody response over WCA alone. The highest
concentration of anti-WCA IgG was observed in mice
injected with WCA/AP, followed by WCA/PTAP,
WCA/PTAH, and WCA/AH (Figure 2). The difference
between WCA/AP and WCA/AH was statistically
significant.
Effect of AH vs. AP on antibody and IL-17 responses
Since phosphate treatment of the AH and AP adjuvants
did not enhance the immunostimulatory effect of these
adjuvants, subsequent experiments were conducted with
AH and AP only. Mice were injected with 3 different
doses of WCA alone or combined with AH or AP.
Blood was collected after two and three injections for
the determination of anti-WCA antibody concentrations,
and after three injections for IL-17 production. The
adjuvants significantly enhanced the antibody response
to WCA at all three doses and after two as well as three
immunizations (Figure 3). The anti-WCA IgG concen-
tration generally increased with increasing dose and
after more immunizations. At the lowest dose of WCA
(10
6 cells), the mice that received WCA/AP generated a
stronger antibody response than mice injected with
WCA/AH. At the intermediate dose (10
7 cells), WCA/
AP induced a stronger antibody response after two
injections, while there was no difference between the
WCA/AP and WCA/AH groups after three injections.
There was also no difference between WCA/AP and
WCA/AH after two injections of the highest dose (10
8
cells), but after three injections the mice that received
WCA/AH had the highest IgG concentration. Previous
experiments showed that anti-WCA IgG concentrations
> 10,000 units/mL are protective upon challenge in
mice [19]. These values were consistently obtained after
three injections with 10
7 and 10
8 cells when formulated
with AP, and with 10
8 cells when formulated with AH.
Figure 1 Phosphate treatment of aluminum hydroxide adjuvant and aluminum phosphate adjuvant prevented the adsorption of
bacterial pneumococcal cells. Light microscopy of WCA mixed with the aluminum-containing adjuvants, aluminum hydroxide adjuvant (AH),
aluminum phosphate adjuvant (AP), phosphate-treated AH (PTAH) and phosphate-treated AP (PTAP). The bacteria were stained with gentian
violet, and the suspensions were examined using a 100× oil objective.
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dose-dependent with AP generating a stronger antibody
response at lower antigen doses.
The adjuvants AH and AP have opposite surface
charges at pH 6-7 resulting in different affinities for pro-
teins with different isoelectric points. To determine if
these differences affect which WCA proteins induce an
antibody response, an immunoblot was performed with
WCA as substrate and pooled plasma from mice in each
of the vaccine groups (Figure 4). The antibodies reacted
with a range of proteins varying in size from less than
20 kD to over 200 kD. Consistent with the ELISA
results, the bands from mice immunized with the high-
est dose of WCA in combination with AH had the
greatest intensity. Antibodies from mice injected with
adjuvanted WCA reacted with more proteins than anti-
bodies from mice injected with WCA only. In addition,
there were several proteins in the 30 - 60 kD range that
reacted only with antibodies from mice immunized with
AH or with AP-adjuvanted vaccines (Figure 4).
The concentration of IL-17A (IL-17) was determined
in the supernatant of whole blood cultures following
incubation with WCA for 6 days. A significant concen-
tration of IL-17 was only detected in cultures from mice
injected with the intermediate and high dose of WCA in
combination with AH. There was no detectable IL-17 in
blood cultures from any of the other groups (Figure 5).
Stability of the WCA/AH vaccine formulation
To determine the effect of prolonged storage of the
WCA/AH vaccine on the immune response, the high
dose of WCA (10
8 cells/dose) was prepared with or
without AH and stored for 4 months at 4°C. Mice were
injected 3 times with stored and freshly prepared vac-
cines and the immune response was analyzed as
described above. A greater IgG response was observed
after three compared with two injections. The IgG
response obtained with the stored vaccine formulation
was slightly lower than that obtained with the freshly
prepared formulation (geometric mean of freshly pre-
pared WCA was 9,073 vs. 6,754 for stored WCA; geo-
metric mean of freshly prepared WCA/AH was 60,256
vs. 41,688 for stored WCA/AH), but the difference was
not statistically significant (Figure 6A). Importantly, the
IgG titers in mice immunized with the stored vaccine
were well above the minimum protective level of 10,000
units/mL. There was no difference in the concentration
of IL-17 in supernatants of whole blood cultures of
mice immunized with WCA/AH (Figure 6B).
Discussion
Vaccines against pneumococcal disease for use in devel-
oping countries should be safe, effective against a broad
range of serotypes and affordable. The existing conju-
gate vaccines offer protection against the serotypes
included in the vaccine which were selected based on
their prevalence in North America and Europe, and are
predicted to provide incomplete protection against
pneumococcal infections in Asia and Africa. In addition,
these conjugate vaccines are expensive to produce. The
work in this report demonstrates that a vaccine com-
posed of killed whole cell, nonencapsulated pneumo-
cocci and formulated with AH, induces a strong
antibody and IL-17 response. Both the antigen and adju-
vant are relatively inexpensive suggesting that the vac-
cine will be affordable for use in developing countries.
Previous work with a simple protein antigen, alpha
casein, indicated that the strength of adsorption of anti-
gens onto aluminum-containing adjuvants is inversely
related to the antibody response to these antigens [18].
A similar relationship was found with a larger and more
complex antigen, hepatitis B surface antigen (HBsAg),
but the negative effect of a high adsorptive coefficient
was not as strong as with alpha casein [20]. The antigen
used in the current studies, WCA, consists of killed
whole bacterial cells and some soluble bacterial proteins.
WCA was mixed with four aluminum-containing adju-
vants with different surface properties to determine if
differences in adsorptive capacity and adsorptive
Figure 2 IgG titers in mice injected with vaccines with different
types of aluminium-containing adjuvants. Mice (n = 8/group)
were injected twice with WCA (10
7 cells/dose) alone or combined
with four different aluminum-containing adjuvants. The IgG titer in
serum was determined two weeks after the second injection. The
symbols represent individual mice and the horizontal line indicates
the geometric mean. The geometric means of groups with different
letters are different at p < 0.05.
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Page 5 of 10Figure 3 IgG titers in mice injected with vaccines formulated with AH and AP and different doses of WCA. Mice were immunized twice
with WCA at 10
6 cells (A), 10
7 cells (B) and 10
8 cells (C) per dose, or three times with WCA at 10
6 cells (D), 10
7 cells (E) and 10
8 cells (F) per
dose. The symbols represent individual mice (n = 4/group for WCA alone and n = 8 for WCA/AH and WCA/AP) and the horizontal line indicates
the geometric mean.
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values should be interpreted with caution because of the
complex nature of WCA, they indicate a range of
adsorptive properties for the four adjuvants. The highest
values were measured for AH while adjuvants with
more surface phosphates had a lower affinity for WCA.
This suggests that at least some of the molecules in
WCA are phosphorylated or associated with phospholi-
pid membranes, and are adsorbed by the ligand
exchange mechanism.
T h ea n t i b o d yr e s p o n s et ot h ev a c c i n ef o r m u l a t i o n s
with the four adjuvants with broadly divergent adsorp-
tive capacities and coefficients for WCA indicated that
the aluminum-containing adjuvant potentiated the
immune response even when the antigen was not
adsorbed. In addition, the strength of adsorption was
not a significant factor in immunopotentation. Alumi-
num adjuvants may enhance the immune response to
soluble antigens by adsorbing the antigens onto the
adjuvant particles that are more readily phagocytised by
antigen-presenting cells [21]. Antigen adsorption by the
adjuvant may be less relevant when the antigen com-
prises killed whole cell bacteria as the bacteria are about
1 micrometer in diameter while the primary particles of
the adjuvant are smaller than 50 nm [11]. Since changes
in adsorption through phosphate treatment of the adju-
vants did not affect the antibody response, subsequent
experiments focused on AH and AP.
The protective immune response induced by conjugate
vaccines is based on serotype-specific anti-polysacchar-
ide antibodies. In contrast, the immune response against
WCA involves antibodies directed against protein anti-
gens and Th17 cells. Antibodies induced by WCA can
provide protection against systemic disease, but they do
not protect against nasopharyngeal colonization in mice
[7,9]. Nasopharyngeal colonization was inhibited by CD4
+ T cells that secrete IL-17, and the concentration of IL-
17 in WCA-stimulated whole blood cultures was inver-
sely correlated with the degree of nasopharyngeal colo-
nization following intranasal challenge [10]. Infection of
naïve mice with S. pneumonia induced Th17 cells which
provided enhanced clearance of the bacteria upon sec-
o n d a r yc h a l l e n g e[ 2 2 ] .T h ep r o t e c t i v er o l eo fI L - 1 7
resides in the induction of secretion of antimicrobial
peptides and chemokines that attract monocytes and
neutrophils to the site of infection [23,24]. IL-17 is also
involved in the protection against other extracellular
bacterial pathogens such as Bordetella pertussis, intracel-
lular bacterial pathogens including Mycobacterium
tuberculosis, and fungal pathogens, indicating an impor-
tant role against infections at mucosal surfaces and in
the lung. However, an excessive IL-17 response may be
detrimental and cause extensive tissue damage [23,24].
It has been suggested that Th17 cells are critical for vac-
cine-induced memory immune responses, and enhan-
cing and regulating the Th17 response may be
important in vaccine design [24]. In our studies, the
combination of WCA with AH was critical for the
induction of a population IL-17 producing cells
Figure 4 Antigen specificity of IgG from mice injected with
vaccines formulated with AH and AP. Immunoblot of WCA with
antibodies in pooled plasma from mice injected three times with
WCA only at 10
8/dose (lane 1); WCA/AP at 10
8/dose (lane 2), 10
7/
dose (lane 3), 10
6/dose (lane 4); and WCA/AH at 10
8/dose (lane 5),
10
7/dose (lane 6), 10
6/dose (lane 7). Plasma was collected 2 weeks
after the last injection.
Figure 5 Vaccines of WCA formulated with AH, but not with
AP or vaccines without adjuvants induced an IL-17 response.
IL-17 concentration in the supernatant of whole blood cultures
incubated for 6 days with WCA (10
7/mL). The blood was collected
from mice injected three times with WCA, WCA/AH or WCA/AP at
10
6 cells/dose, 10
7 cells/dose or 10
8 cells/dose. The bars indicate the
mean ± SEM of 8 mice per group. * p < 0.05; ** p < 0.005 (WCA/
AH vs. WCA and WCA/AH vs. WCA/AP).
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nor WCA with AP induced a significant IL-17 response,
even though AP greatly enhanced the antibody response
t oW C A .S u c had r a m a t i cd i f f e r e n c ei nt h eq u a l i t yo f
the immune response between vaccines formulated with
AH and vaccines formulated with AP was unexpected.
The induction of Th17 cells in S. pneumoniae infec-
tion is dependent on TLR2 [22]. The ligands for TLR2
include molecular components of Gram-positive bacteria
such as lipoproteins [25,26]. The induction of Th17 cells
by WCA/AH and not by WCA/AP suggests that these
ligands are not available in the WCA/AP formulation,
possibly due to strong electrostatic adsorption.
There are few published reports in which the
immune responses to bacterial vaccines formulated
with AP vs. AH are directly compared. In one study,
acellular pertussis antigens combined with AH induced
a stronger antibody response and greater protection
upon intranasal challenge with Bordetella pertussis
compared with AP, but the basis of the increased pro-
tection was not further investigated [27]. Th17 cells
are induced during infection with Bordetella pertussis,
but antibody-mediated depletion of IL-17 only had a
modest effect on the bacterial loads in the lungs of
experimentally infected mice [28]. Two types of vac-
cines, a whole cell and an acellular pertusiss vaccine,
are used to protect against whooping cough. Both vac-
cines are effective, but vaccination of mice with a
whole cell pertussis vaccine induced Th17 cells,
whereas these cells were not induced by the acellular
vaccine [29,30]. The role of adjuvants was not specifi-
cally addressed in these studies.
The basis for the difference in immune response gen-
erated by WCA formulated with AH vs. AP is not
entirely clear, but it is likely that the greater affinity of
AH for WCA proteins contributed to this effect. The
adsorptive strength, determined as the adsorptive coeffi-
cient, of AH was 2.5 times that of AP. Previous work
showed that a high adsorptive strength may interfere
with the antibody response and the T cell response,
probably because there is insufficient release of antigen
from the adjuvant to interact with B cells and for anti-
gen processing and presentation [18]. A similar effect
was observed at the lower doses of WCA in which a sig-
nificantly stronger antibody response was obtained with
AP in comparison with AH. At higher doses, the differ-
ence between AP and AH disappeared and AH induced
a stronger antibody response than AP at the highest
antigen dose.
Immunoblot analysis revealed qualitative and quantita-
tive differences in the antigenic proteins recognized by
antibodies from the mice injected with different WCA
formulations. The antibodies from mice injected with
adjuvanted WCA reacted with more proteins than those
from mice injected with non-adjuvanted WCA. Antibo-
dies from mice injected with WCA/AH and WCA/AP
reacted with an overlapping, but different set of pro-
teins. The surface of AH and AP have opposite charges
at pH 6-7 resulting in different affinities for individual
proteins within the WCA. This may in turn affect which
Figure 6 Immunogenicity of the WCA/AH vaccine formulation stored for 4 months at 4°C. Mice were immunized three times with WCA
(10
8 cells/dose) and WCA/AH stored at 4°C for four months (s) or with freshly prepared WCA and WCA/AH (f). The IgG titer was determined in
plasma collected 2 weeks after the last injection. The IL-17 concentration was determined in the supernatant of whole blood cultures stimulated
with WCA.
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bodies. Further studies are necessary to determine the
biological significance of these differences in antibody
specificities.
Long term stability of vaccines is an important consid-
eration. In order to assess the stability of the WCA/AH
vaccine formulation, the effect of prolonged storage at
4°C on the immune response was determined. There
was no significant difference between the stored and
freshly prepared formulations indicating that the WCA/
AH is quite stable.
Conclusions
The goal of these experiments was to determine the
optimal formulation of a killed pneumococcal vaccine
with aluminium-containing adjuvants. The data indicate
that formulation of WCA with AH induces a strong
antibody and Th17 response, and AH is the preferred
choice over AP for vaccines for intramuscular adminis-
tration. The marked differences in the antibody and cel-
lular response to the two aluminum-containing
adjuvants underscores the importance of proper pre-for-
mulation studies in preparing safe and effective vaccines
[31,32].
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